Assay of guanidine in pharmaceutical formulations

Importance of the Topic

Guanidine hydrochloride is a therapeutic agent for neuromuscular disorders such as Lambert–Eaton myasthenic syndrome and botulism. Precise quantification of guanidine in pharmaceutical formulations is critical for drug efficacy and safety, yet conventional GC and HPLC methods rely on time-consuming derivatization steps. A direct ion chromatography (IC) approach can streamline analysis, reduce sample preparation and improve laboratory throughput.

Aims and Study Overview

This work aimed to establish and validate an ion chromatographic assay for guanidine in solid dosage forms. The method employs a Thermo Scientific RFIC system with an electrolytically generated methanesulfonic acid (MSA) eluent and suppressed conductivity detection, eliminating the need for chemical derivatization. The Dionex IonPac CS20 cation-exchange column was selected to separate guanidine from common matrix cations in under 8 minutes.

Instrumentation

• Thermo Scientific Dionex ICS-5000+ RFIC system (DP dual pump, DC detector compartment)
• Dionex AS-AP autosampler with cooling tray
• Dionex EGC 500 MSA eluent generator cartridge
• Dionex CR-CTC 500 continuously regenerated cation trap column
• Dionex CDRS 600, 2 mm suppressor for suppressed conductivity detection
• Dionex IonPac CS20 analytical column (2 × 250 mm) with CG20 guard column (2 × 50 mm)

Methodology

Standard and sample preparation involved a 1,000 mg/L primary guanidine stock solution in Type I water, diluted to calibration levels of 0.2–10 mg/L. A simulated pharmaceutical matrix was prepared by dissolving paracetamol tablets, filtering and spiking with known guanidine amounts. Key chromatographic conditions: isocratic elution with 50 mM MSA at 0.3 mL/min, 40 °C column temperature, 2.5 µL injection, 8 min run time.

Main Results and Discussion

Separation of guanidine from alkali and alkaline-earth cations was achieved within 8 minutes with baseline resolution from magnesium. Calibration was linear across 0.1–10 mg/L (R2 = 0.9999). Precision (n = 3) yielded retention time RSD ≤ 0.44% and peak area RSD ≤ 2.11%. Method sensitivity produced LOD of 0.0045 mg/L and LOQ of 0.0125 mg/L. Spike-recovery experiments in the simulated matrix demonstrated recovery between 100% and 103%. Robustness testing (±10% variations in flow, temperature, eluent concentration) confirmed method stability, with eluent concentration showing the greatest influence on chromatographic parameters.

Benefits and Practical Applications

• Derivatization-free analysis reduces sample preparation time and consumable usage
• Automated RFIC operation with only deionized water as carrier simplifies maintenance
• High sensitivity and precision suitable for assay and trace-level determination
• Rapid throughput (8 min per injection) for quality control environments

Future Trends and Potential Applications

Adaptation of this IC approach to other small basic drug substances and related impurities could broaden its utility. Integration with mass spectrometric detection may enhance selectivity for complex matrices. Further development of greener eluents and miniaturized IC platforms will support sustainability and portable analytics.

Conclusion

An RFIC method using a Dionex IonPac CS20 column and suppressed conductivity detection provides a rapid, robust, and derivatization-free assay for guanidine in pharmaceutical formulations. The method meets USP <1225> validation criteria, offering a practical solution for routine quality control.

References

1. Keogh M; Sedehizadeh S; Maddison P. Treatment for Lambert–Eaton myasthenic syndrome. Cochrane Database Syst. Rev. 2011; CD003279.
2. Verschuuren JJ, Wirtz PW, Titulaer MJ, Willems LN, van Gerven J. Available treatment options for Lambert–Eaton myasthenic syndrome. Expert Opin. Pharmacother. 2006;7(10):1323–1336.
3. Constantinos CA, Koupparis MA. Automated flow injection pseudotitrations of amines and hydrohalide salts. Analyst. 1988;113:755–759.
4. Blumhardt LD, Joekes AM, Marshall J, Philalithis PE. Guanidine treatment and impaired renal function in Eaton–Lambert syndrome. Br. Med. J. 1977;1(6066):946–947.
5. Majidano SA, Khuhawar MY. GC determination of guanidino compounds in uremic patients using glyoxal. J. Chromatogr. Sci. 2012;50(5):380–386.
6. Zounr RA et al. Improved GC determination of guanidino compounds using IVA and ECF. Anal. Sci. 2016;32(2):141–146.
7. Palaitis W, Curran JRH. HPLC assay for guanidine salts based on acetylacetone derivatization. J. Chromatogr. Sci. 1984;22(3):99–103.
8. Yamamoto Y et al. Quantitative analysis of methylguanidine and guanidine in fluids by HPLC-fluorescence. J. Chromatogr. 1979;162(1):23–29.
9. USP General Chapter <1225> Validation of Compendial Methods. USP 36–NF 31; 2013.
10. USP General Chapter <621> Chromatography. USP 36–NF 21; 2013.